Key facts
- It has raised $1.4M; the latest was Seed Round ($1.4M) in Aug 2025.
- Notable investors include SOSV, IndieBio, Esther Dyson, Clinton Bybee, Denise Kellen — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Circadian OS
- ·The full record, as it builds
Funding rounds
No funding rounds for Circadian OS are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Circadian OS
Developer of a biotechnology platform intended to optimize the timing of immunotherapy for better patient outcomes. The company offers technology that synchronizes immune system activity with treatment schedules, developed in collaboration with pharmaceutical and clinical partners, enabling oncologists and healthcare providers to improve treatment effectiveness and provide more tailored cancer care.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2023
- Employees
- 3
- Website
- circadian-os.com/
- Ownership
- Privately Held (backing)
Circadian OS doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Circadian OS shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Circadian OS in its N-PORT filings yet. We sweep new filings monthly.